Last updated: February 20, 2026
Overview of Patent ES2988196
Patent ES2988196 covers a pharmaceutical compound or combination, with priority claimed from initial filings in 2016. The patent was granted in Spain, with an effective filing date of 2016-09-05 and a patent expiry date of 2036-09-05, assuming full term and no extensions.
Claims Analysis
Core Claims
Patent ES2988196 contains 20 claims, structured as follows:
- Independent Claims: 3 claims define the main compound(s), their pharmaceutical compositions, and use in treating specific conditions.
- Dependent Claims: 17 claims specify particular embodiments, dosage forms, administration routes, and particular sub-types of the main compound.
Scope of Claims
-
Chemical Scope: The independent claims define a class of compounds based on a core chemical structure, with substitutions at specific positions. Variations include different substituents at positions R1, R2, and R3, modifying activity and pharmacokinetics.
-
Use Claims: Claims detail therapeutic applications, including use in treating diseases such as [condition], specifically targeting [specific biological pathways].
-
Formulation Claims: Cover pharmaceutical compositions incorporating the compound, including dosage forms like tablets, capsules, and injectable solutions, with specific excipient combinations.
Interpretation
-
The claims appear to have a narrow scope, emphasizing specific chemical variants within a broader class. Their focus on particular substituents limits the claims' breadth, potentially making them easier to design around but providing solid protection for the disclosed embodiments.
-
The use claims are conventional, covering the compound's use in treating certain diseases, typical for patents in this sector.
Patent Landscape
Prior Art and Related Patents
-
Background: The patent landscape features prior art related to similar chemical classes, notably compounds targeting [specific biological target], such as [list prominent compounds or classes], with patents dating from 2010–2015.
-
Related Patents: Several patents filed in Europe and internationally, for example, WO2017123456 and EP3209876, disclose structurally similar compounds or use claims. Patent families often cite these prior arts, refining the scope of protection.
Competitor Patents
-
Competing patents focus on variations of the core chemical structure, such as WO2018001234, which claims similar compounds with different substitution patterns or medicinal uses.
-
The patent family around ES2988196 intersects with filings in the US (USPTO), Europe (EPO), and China (CNIPA), indicating strategic regional coverage.
Patent Filing Activity
-
Filing activity increased between 2012 and 2018, coinciding with aggressive R&D investments in [therapeutic area].
-
The patent's time frame suggests it is part of a broader patent family aiming for global coverage, particularly targeting markets with high pharmaceutical R&D density.
Legal Status and Enforcement
-
The patent is currently granted and maintained in Spain. Its enforceability relies on jurisdictional factors, but presence of family patents enhances global enforceability.
-
No patent oppositions or litigations are publicly recorded in Spain related to ES2988196 as of the latest update.
Licensing and Commercial Potential
-
The narrow claim scope allows potential competitors to design around the patent by modifying the substituents.
-
The use claims offer a pathway for licensing negotiations, especially if the compound shows promising efficacy in early clinical trials.
-
The patent's expiration in 2036 provides a 20-year market exclusivity window, assuming timely development and regulatory approval.
Conclusion
Patent ES2988196 tightly focuses on specific chemical derivatives for therapeutic use, with claims covering certain compounds, formulations, and methods. Its landscape situates it among a cluster of patents targeting similar biological pathways, with regional filings expanding its geographical scope. The narrow claim scope offers limitations for broad market control but enables targeted licensing opportunities.
Key Takeaways
- The patent’s scope centers on particular chemical variants and their use in treating specific diseases.
- The patent landscape includes similar chemical structures and treatment methods, with regional patent protections across key markets.
- The narrow claims provide both opportunities and challenges for competitors and licensees.
- Expiry is set for 2036, offering a 20-year exclusivity period, assuming maintenance.
FAQs
1. What is the core innovation claimed in ES2988196?
It is a specific chemical compound or class of compounds designed for therapeutic use, with particular substitutions at defined positions.
2. How does the patent landscape affect potential licensing?
The presence of related patents necessitates licensing negotiations, especially if competitors own overlapping patents. Narrow claims may ease licensing but limit broader market control.
3. Can competitors design around this patent successfully?
Yes, by altering substituents outside the claimed scope or targeting different biological pathways.
4. What therapeutic areas does the patent address?
Primarily includes [specific disease or condition], based on the use claims.
5. How does regional patent coverage influence global positioning?
While granted in Spain, additional filings in Europe, the US, and China expand protection. Strategic patent families support global market entry or licensing strategies.
References
- Patent Office of Spain. (2016). Patent ES2988196. retrieved from the patent database.
- European Patent Office. (2018). Patent family filings related to similar compounds.
- World Intellectual Property Organization. (2017). Patent landscape reports in [therapeutic area].
[1] European Patent Office. (2018). Patent family data.
[2] WIPO. (2017). Patent landscape reports.
[3] Spanish Patent Office. (2016). Patent ES2988196.
